504594 | Gemcitabine, HCl - CAS 122111-03-9 - Calbiochem

504594
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₉H₁₁F₂N₃O₄ • HCl 122111-03-9

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      5.04594.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 50 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA bioavailable, moderately toxic, deoxyctytidine analog with anti-metabolite and anti-tumor properties. Shown to be effective against a variety of tumors and blocks the growth of cancer cells in culture (IC 50 = 8.7, 57, 3.7, and 36 nM for L1210, CEM, Caco2, and HeLa cells, respectively). Following its uptake into cells by nucleoside transporters it is phosphorylated to its mono (dFdCMP), di (dFdCDP), and triphosphorylated (dFdCTP) forms by deoxycytidine kinase. dFdCDP and dFdCTP are reported to inhibit the activity of ribonucleotide reductase and impede DNA synthesis and repair mechanisms and induce cell death. Blocks the progression of cells through the G1/S phase. The dFdCTP is shown to compete with endogenous deoxycytidine triphosphate (dCTP) for incorporation into DNA and against CTP into RNA. Gemcitabine is also shown to block mitochondrial DNA polymerase γ. Works synergistically with other chemotherapeutic agents to enhance their cytotoxicity. Its half life is reported to be 42 to 94 min (depending upon the age and sex of the individual).
          Catalogue Number504594
          Brand Family Calbiochem®
          SynonymsLY188011, dFdC, dFdCyd, 2ʹ,2ʹ-Difluoro-2ʹ-deoxycytidine, HCl, 2ʹ-Deoxy-2ʹ,2ʹ-difluorocytidine, HCl, 4-Amino-1-((2R,5S)-3,3-difluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, HCl, Ribonucleotide Reductase Inhibitor II, RNR Inhibitor II
          References
          ReferencesHung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.
          Product Information
          CAS number122111-03-9
          FormWhite powder
          Hill FormulaC₉H₁₁F₂N₃O₄ • HCl
          Chemical formulaC₉H₁₁F₂N₃O₄ • HCl
          Hygroscopic Hygroscopic
          ReversibleN
          Applications
          Biological Information
          Primary TargetDNA
          Secondary targetDNA polymerase
          Purity≥99% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 62-63

          Possible risk of impaired fertility.
          Possible risk of harm to the unborn child.
          S PhraseS: 36/37-53

          Wear suitable protective clothing and gloves.
          Avoid exposure - obtain special instructions before use.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Carcinogenic / Teratogenic
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Hung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision01-July-2013 JSW
          SynonymsLY188011, dFdC, dFdCyd, 2ʹ,2ʹ-Difluoro-2ʹ-deoxycytidine, HCl, 2ʹ-Deoxy-2ʹ,2ʹ-difluorocytidine, HCl, 4-Amino-1-((2R,5S)-3,3-difluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, HCl, Ribonucleotide Reductase Inhibitor II, RNR Inhibitor II
          DescriptionA bioavailable, moderately toxic, deoxyctytidine analog with anti-metabolite and anti-tumor properties. Shown to be effective against a variety of tumors and blocks the growth of cancer cells in culture (IC 50 = 8.7, 57, 3.7, and 36 nM for L1210, CEM, Caco2, and HeLa cells, respectively). Following its uptake into cells by nucleoside transporters it is phosphorylated to its mono (dFdCMP), di (dFdCDP), and triphosphorylated (dFdCTP) forms by deoxycytidine kinase. dFdCDP and dFdCTP are reported to inhibit the activity of ribonucleotide reductase and impede DNA synthesis and repair mechanisms and induce cell death. Blocks the progression of cells through the G1/S phase. The dFdCTP is shown to compete with endogenous deoxycytidine triphosphate (dCTP) for incorporation into DNA and against CTP into RNA. Gemcitabine is also shown to block mitochondrial DNA polymerase γ. Works synergistically with other chemotherapeutic agents to enhance their cytotoxicity. Its half life is reported to be 42 to 94 min (depending upon the age and sex of the individual).
          FormWhite powder
          Intert gas (Yes/No) Packaged under inert gas
          CAS number122111-03-9
          Chemical formulaC₉H₁₁F₂N₃O₄ • HCl
          Purity≥99% by HPLC
          SolubilityH₂O (25 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Carcinogenic / Teratogenic
          ReferencesHung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.